Compare IMMP & URG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IMMP | URG |
|---|---|---|
| Founded | 1987 | 2004 |
| Country | Australia | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Precious Metals |
| Sector | Health Care | Basic Materials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 264.9M | 477.8M |
| IPO Year | N/A | N/A |
| Metric | IMMP | URG |
|---|---|---|
| Price | $2.64 | $1.25 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $2.52 |
| AVG Volume (30 Days) | 1.7M | ★ 9.9M |
| Earning Date | 02-22-2026 | 11-03-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $3,306,742.00 | ★ $39,411,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $183.54 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | 31.28 | ★ 138.94 |
| 52 Week Low | $1.32 | $0.55 |
| 52 Week High | $3.53 | $2.35 |
| Indicator | IMMP | URG |
|---|---|---|
| Relative Strength Index (RSI) | 75.51 | 42.18 |
| Support Level | $1.67 | $1.17 |
| Resistance Level | $2.68 | $1.46 |
| Average True Range (ATR) | 0.25 | 0.07 |
| MACD | 0.09 | 0.01 |
| Stochastic Oscillator | 51.08 | 31.03 |
Immutep Ltd is a Phase three clinical biotechnology company developing novel Lymphocyte Activation Gene-3 (LAG-3) related immunotherapies for cancer and autoimmune disease. It has a diversified product portfolio that harnesses LAG-3's ability to stimulate the body's immune response to fight cancer or suppress the immune system to treat autoimmune disease. The company is focused on advancing its product candidate, eftilagimod alfa (efti), through its registrational Phase three clinical trial towards marketing approval in first-line non-small cell lung cancer (1L NSCLC). The other product candidates in its portfolio include TACTI-004, TACTI-003, AIPAC-003, TACTI-002, INSIGHT-005, and others, being developed as potential therapies for various cancers and autoimmune diseases.
Ur-Energy Inc is engaged in uranium mining and recovery operations, with activities including the acquisition, exploration, development, and production of uranium mineral resources located in Wyoming. The company owns and operates the Lost Creek in-situ recovery uranium facility in south-central Wyoming, Lost Creek received an amendment to its license allowing the expansion of mining activities within the existing Lost Creek Project and the adjacent LC East Project.